Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2001-04-13
2009-12-15
Lam, Ann Y (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000, C435S007920
Reexamination Certificate
active
07632647
ABSTRACT:
The present invention relates to materials and procedures for evaluating the prognosis of patients suffering from acute coronary syndromes. In particular, the level of BNP, or a marker related to BNP, in a patient sample, alone or in combination with one or more other prognostic markers, provides prognostic information useful for predicting near-term morbidity and/or mortality across the entire spectrum of acute coronary syndromes, including unstable angina, non-ST-elevation non-Q wave myocardial infarction, ST-elevation non-Q wave MI, and transmural (Q-wave) MI.
REFERENCES:
patent: 5206140 (1993-04-01), Marder et al.
patent: 5290678 (1994-03-01), Jackowski
patent: 5352587 (1994-10-01), Chang et al.
patent: 5422393 (1995-06-01), Bricker et al.
patent: 5480792 (1996-01-01), Buechler et al.
patent: 5525524 (1996-06-01), Buechler et al.
patent: 5580722 (1996-12-01), Foulkes et al.
patent: 5604105 (1997-02-01), Jackowski
patent: 5631171 (1997-05-01), Sandstrom et al.
patent: 5679526 (1997-10-01), Buechler et al.
patent: 5747274 (1998-05-01), Jackowski
patent: 5786163 (1998-07-01), Hall
patent: 5795725 (1998-08-01), Buechler et al.
patent: 5824799 (1998-10-01), Buechler et al.
patent: 5851776 (1998-12-01), Valkirs
patent: 5885527 (1999-03-01), Buechler
patent: 5922615 (1999-07-01), Nowakowski et al.
patent: 5939272 (1999-08-01), Buechler et al.
patent: 5947124 (1999-09-01), Buechler et al.
patent: 5955377 (1999-09-01), Maul et al.
patent: 5985579 (1999-11-01), Buechler et al.
patent: 6019944 (2000-02-01), Buechler
patent: 6113855 (2000-09-01), Buechler
patent: 6117644 (2000-09-01), DeBold
patent: 6143576 (2000-11-01), Buechler
patent: 6147688 (2000-11-01), Clair
patent: 6156521 (2000-12-01), Buechler et al.
patent: 6171870 (2001-01-01), Freitag
patent: 6309888 (2001-10-01), Holvoet et al.
patent: 6461828 (2002-10-01), Stanton et al.
patent: 6627457 (2003-09-01), Pandian et al.
patent: 6670138 (2003-12-01), Gonzalez-Zulueta et al.
patent: 6756483 (2004-06-01), Bergmann et al.
patent: WO91/09627 (1991-07-01), None
patent: WO 00/22439 (2000-04-01), None
patent: WO 02/083913 (2002-10-01), None
Newby et al., “Bedside Multimarker Testing for Risk Stratification in Chest Pain Units; The Chest Pain Evaluation by Creatine Kinase-MB, Myoglobin, and Troponin I (Checkmate) Study” Circulaton, (Apr. 10, 2001); 103: pp. 1832-1837.
Antman et al., “Cardiac-specific Troponin I Levels to Predict the Risk of Mortality in Patients with Acute Coronary Syndromes”, The New England Journal of Medicine, (1996), pp. 1342-1349, vol. 335, No. 18.
Richards et al., [“Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction”, Heart, (1999); 81: 114-120].
Huttunen et al., Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. The Journal of Biological Chemistry, 275:40096-4010, 2000.
Mussack et al., Early cellular brain damage and systemic inflammatory response after cardiopulmonary resuscitation or isolated severe head trauma: a comparative pilot study on common pathomechanisma.
Yakoviev et al., Activation of CPP32-Like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury. The Journal Neuroscience, 17(19):7415-724, 1997.
International Search Report for international application No. PCT/US04/26984.
Notice of References Cited, PTO-892, Part of Paper No. 20041202 from U.S. Appl. No. 10/225,082, filed Aug. 20, 2002.
Alexander et al., “30-Day and 6-Month Nortality in Proportional to Magnitudr of Peak Creatine Kinase Elevation in the Non-ST-elevation Acute Coronary Syndromes,” Circulation (Supp.), 1998, p. I-629.
Antman et al., “Cardiac-Specific Troponin I Levels to Predict the Risk of Mortality in Patients with Acute Coronary Syndromes,” The New England Journal of Medicine, 1996, p. 1342-1349, vol. 335, No. 18.
Antman et al., “Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non-Q-Wave Myocardial Infarction,” Circulation, 1999, p 1593-1601, vol. 100.
Arakawa et al., “Relationship Between Plasma Level of Brain Natriuretic Peptide and Myocardial Infarct Size,” Cardiology, 1994, p. 334-340, vol. 85.
Arakawa et al., “Plasma Brain Natriuretic Peptide Concentrations Predict Survival After Acute Myocardial Infraction,” JACC, Jun. 1996, p. 1656-1661, vol. 27, No. 7.
Berger et al., “B-Type Natriuretic Peptides (BNP and PRO-BNP) Predict Longterm Survival in Patients with Advanced Heart Failure Treated with Atenolol,” Journal of the Heart and Lung Transplantation, 2001, p. 251, vol. 20, No. 2.
Braunwald et al., “Unstable Angina: Diagnosis and Management,” Clinical Practice Guideline No. 10 (amended), AHCRP Publication No. 94-0602, Rockville, MD: Department of Health and Human Services, 1994.
Cannon et al., “Invasive Versus Conservative Strategies in Unstable Angina and Non-Q-Wave Myocardial Infarction Following Treatment with Tirofiban: Rationale and Study Design of the International TACTICS-TIMI18 Trial,” Am. J. Cardiology, 1998, p. 731-736, vol. 82.
Cannon et al., “Oral Glycoprotein llB/llla Inhibition with Orgofiban in Patients with Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) Trial,” Circulation, 2000, p. 149-156, vol. 102.
Cheng et al, “A Rapid Bedside Test for B-Type Peptide Predicts Treatment Outcomes in Payients Admitted for Decompensated Heart Failure: A pilot Study,” Journal of the American College of Cardiology, 2001, p. 386-391, vol. 37, No. 2.
Dao et al., “Utility of B-Type Natriuretic Peptide in the Diagnosis of Congestive Heart Failure in an Urgent- Care Setting,” Journal of the American College of Cardiology, 2001, p. 379-385, vol. 37, No. 2.
Darbar et al., “Diagnostic Value of B-Type Natriuretic Peptide Concentrations in Patients with Acute Myocardial Infarction,” Am. J. Cardiology, 1996, p. 284-287, vol. 78.
Fischer et al., “Evaluation of a New, Rapid Bedside Test for . . . ,” Clinical Chemistry, 2001, p. 591-594, vol. 47, No. 3.
Grayburn et al., “Perflenapent Emulsion (EchoGen®): A New Long-Acting Phase-Shift Agent for Contrast Echocardiology,” Clinical Cardiology, 1997 , p. l-12-l-18, vol. 20 (Supp l).
Hama et al., “Rapid Ventricular Induction of Brain Natriuretic Peptide Gene Expression in Experimental Acute Mycocardial Infarction,” Circulation, 1995, p. 1558-1564, vol. 92.
Hamm et al., “Benefit of Abciximab in Patients with refractory Unstable Angina in Relation to serum Troponin T Levels,” New England Journal of Medicine, 1999, p. 1623-1629, vol. 340, No. 21.
Horio et al., “Serial Changes in Atrial and Brian Natriuretic Peptides in Patients with Acute Myocardial Infarction Treated with early Coronary Angioplasty,” American Heart Journal, 1993, p. 293-299, vol. 126.
Hunt et al., “The Amino-Terminal Portion of Pro-Brain Natriuretic Peptide (Pro-BNP) Circulates in Human Plasma,” Biochemical and Biphysical Research Communications, 1995, p. 1175-1183, vol. 214, No. 3.
Kikuta et al., “Increased Plasma Levels of B-Type Natriuretic Peptide in Patients with Unstable Angina,” American Heart Journal, 1996, p. 101-107, vol. 132, No. 1.
Klootwijk et al., “Acute Coronary Syndromes: Diagnosis,” The Lancet, Jun. 1999, p. 1109-1113, vol. 132.
Kyriakides et al., “Brain Natriuretic Peptide Increases Acutely and Much More Prominently than Atrial Natriuretic Peptide during Coronary Angioplasty,” Clinical Cardiology, 2000, p. 285-288, vol. 23.
Llodyd-Jones et al., “Electrocardiographic and Clinical Predictors of Acute Myocardial Infarction in Patients with Unstable Angina Pectoris,” Am. J. Cardiology, 1998, p. 1182-1186, vol. 81.
Marumoto et al., “Increased Secretion of Atrial and Brain Natriuretic Peptides During Acute Myocardi
Buechler Kenneth F.
Dahlen Jeffrey R.
Valkirs Gunars E.
Biosite Incorporated
Lam Ann Y
Wilson Sonsini Goodrich & Rosati PC
LandOfFree
Use of B-type natriuretic peptide as a prognostic indicator... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of B-type natriuretic peptide as a prognostic indicator..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of B-type natriuretic peptide as a prognostic indicator... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4144398